Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myeloma

Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria

Bone Marrow Transplantation volume 28, pages 29–37 (2001)Cite this article

Abstract

Of the 61 newly diagnosed patients with Bence-Jones (BJ) myeloma presenting to our centre between May 1986 and December 1997, 53 received sequential therapy (ST) comprising infusional chemotherapy (IC) followed by high-dose therapy and autotransplantation with interferon-α2b maintenance. The outcome was compared with 153 IgG and 39 IgA similarly treated myeloma patients. Response to IC and high-dose was comparable between the three subtypes but a significantly higher proportion of patients with BJ myeloma failed to receive high-dose compared to IgG (P = 0.003) and IgA (P = 0.04) myeloma. Median overall survival (OS) of patients with BJ myeloma (2.8 years) and event-free survival (EFS, 1.2 years) was significantly shorter than for patients with IgG myeloma (4.5 years, P = 0.03 and 2.1 years, P = 0.03, respectively). However, among those patients who achieved complete remission there was no difference in OS and EFS between IgG and BJ myeloma. In distinction to IgG myeloma where age and β2M were significant, Cox analysis on presentation features identified performance status and urine total protein as having significant impact on OS. We conclude that achieving CR is an important treatment aim in patients with BJ myeloma, conferring a similar outlook on survival as in patients with the IgG subtype, and there is a need to consider different subtype-specific staging systems when evaluating the results of published or ongoing therapeutic trials. Bone Marrow Transplantation (2001) 28, 29–37.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Powles R, Raje N, Milan S et al. Outcome assessment of a population based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment Bone Marrow Transplant 1997 20: 435–443

    Article  CAS  Google Scholar 

  2. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma Blood 1999 93: 55–65

    CAS  Google Scholar 

  3. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome New Engl J Med 1996 335: 91–97

    Article  CAS  Google Scholar 

  4. Bjorkstrand BB, Ljungman P, Svensson H et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case matched study from the European Group for Blood and Marrow Transplantation Blood 1996 88: 4711–4718

    CAS  Google Scholar 

  5. Kulkarni S, Powles RL, Treleaven JG et al. Impact of previous high-dose therapy on outcome after allografting for multiple myeloma Bone Marrow Transplant 1999 23: 675–680

    Article  CAS  Google Scholar 

  6. Sirohi B, Powles R, Mehta J et al. Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system Br J Haematol 1999 107: 656–666

    Article  CAS  Google Scholar 

  7. Forgeson GV, Selby P, Lakhani S et al. Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients Br J Cancer 1988 58: 469–473

    Article  CAS  Google Scholar 

  8. Raje N, Powles R, Kulkarni S et al. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma Br J Haematol 1997 97: 153–160

    Article  CAS  Google Scholar 

  9. Gore ME, Selby PJ, Millar B et al. The use of verapamil to overcome drug resistance in myeloma Proc Am Soc Clin Oncol 1988 7: 228

    Google Scholar 

  10. Cunningham D, Paz-Ares L, Milan S et al. High dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma J Clin Oncol 1994 12: 759–736

    Article  CAS  Google Scholar 

  11. Raje N, Powles R, Horton C et al. Comparison of marrow vs blood derived stem cells for autografting in previously untreated multiple myeloma Br J Cancer 1997 75: 1684–1689

    Article  CAS  Google Scholar 

  12. Kulkarni S, Powles R, Treleaven J et al. Randomized trial of equal doses of lenograstim and filgrastim for mobilisation of peripheral blood stem cells in patients with hematologic malignancies Bone Marrow Transplant 2000 25: S260

    Article  Google Scholar 

  13. Cunningham D, Powles RL, Malpas J et al. A randomised trial of maintenance interferon following high dose chemotherapy in multiple myeloma; long term follow up results Br J Haematol 1998 102: 495–502

    Article  CAS  Google Scholar 

  14. Kohn J, Riches PG . A cellulose acetate immuno-fixation technique J Immunolog Meth 1978 20: 325–331

    Article  CAS  Google Scholar 

  15. Karinkanta HH, Nieminen EJ . An improved technique for immunofixation of electropherograms Clin Chem 1978 24: 1639–1641

    CAS  Google Scholar 

  16. Watanaba N, Kamel S, Ohkubo A et al. Urinary protein as measured with a pyrogallol red-molybdate complex, manually and in a Hitachi 726 automated analyzer Clin Chem 1986 328: 1551–1554

    Google Scholar 

  17. Gore ME, Selby PJ, Viner C et al. Intensive treatment of multiple myeloma and criteria for complete remission Lancet 1989 2: 879–881

    Article  CAS  Google Scholar 

  18. Kruskal WH, Wallis WA . Use of ranks in one-criterion variance analysis J Am Stat Assoc 1952 47: 583–621

    Article  Google Scholar 

  19. Kaplan EL, Meier P . Non parametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–481

    Article  Google Scholar 

  20. Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples Br J Cancer 1977 35: 1–39

    Article  CAS  Google Scholar 

  21. Cox DR . Regression models and life tables J Roy Stat Soc Br 1972 24: 187–220

    Google Scholar 

  22. BMDP statistical software release 7 . BMDP Statistical Software Manual University of California Press: Berkeley 1992 pp 825–866

    Google Scholar 

  23. Durie BGM, Salmon SE . A clinical staging system for multiple myeloma Cancer 1975 36: 842–854

    Article  CAS  Google Scholar 

  24. Hobbs JR . Immunoglobulins in clinical chemistry Adv Clin Chem 1971 14: 219–317

    Article  CAS  Google Scholar 

  25. Cunningham D, Paz-Ares L, Gore ME et al. High dose melphalan for multiple myeloma: long term follow up data J Clin Oncol 1994 12: 764–768

    Article  CAS  Google Scholar 

  26. Sirohi B, Powles R, Treleaven J et al. Light chain disease (LCD): a different form of myeloma compared with IgG disease Blood 1999 10: (Suppl. 1) 2567

    Google Scholar 

  27. Smolens P, Barnes JL, Kreisberg R . Hypercalcemia can potentiate the nephrotoxicity of Bence Jones proteins J Lab Clin Med 1987 110: 460–465

    CAS  PubMed  Google Scholar 

  28. Howells DPM . Serum albumin and survival in myelomatosis Br Med J 1971 3: 583

    Article  Google Scholar 

  29. McElwain TJ, Powles R . High dose intravenous melphalan for plasma cell leukaemia and myeloma Lancet 1983 2: 822–824

    Article  CAS  Google Scholar 

  30. Jagannath S, Barlogie B, Dicke K et al. Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors Blood 1990 76: 1860–1866

    CAS  Google Scholar 

  31. Sirohi B, Powles R, Kulkarni S et al. Glomerular filtration rate (GFR) as a surrogate marker for transplant-related toxicity and overall outcome in patients of multiple myeloma (MM) homogenously treated with high dose melphalan (HDM) 200/m2 Bone Marrow Transplant 2000 25: (Suppl. 1) 694

    Article  Google Scholar 

  32. Merlini G, Waldenstrom JG, Jayakar S . A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients Blood 1980 55: 1011–1019

    CAS  PubMed  Google Scholar 

  33. Medical Research Council Working Party on Leukemia in adults . Prognostic features in the third MRC myelomatosis trial Br J Cancer 1980 42: 831–840

    Article  Google Scholar 

Download references

Acknowledgements

We thank the David Adams Leukaemia Fund, Bud Flanagan Leukaemia Fund and the Institute of Cancer Research.

Author information

Authors and Affiliations

  1. Leukaemia and Myeloma Units, Royal Marsden NHS Trust, Sutton, Surrey, UK

    B Sirohi, R Powles, S Kulkarni, C Rudin, R Saso, R Lal, S Singhal, J Mehta, C Horton & J Treleaven

  2. Division of Transplantation Medicine, South Carolina Cancer Center and Richland Memorial Hospital, Seven Richland Medical Park, Columbia, SC 29203, USA

    S Singhal & J Mehta

Authors
  1. B Sirohi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Powles
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Kulkarni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Rudin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Saso
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Lal
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Singhal
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C Horton
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J Treleaven
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sirohi, B., Powles, R., Kulkarni, S. et al. Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria. Bone Marrow Transplant 28, 29–37 (2001). https://doi.org/10.1038/sj.bmt.1703093

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703093

Keywords

This article is cited by

Search

Advanced search

Quick links